June 16, 2020 -- Contract development and manufacturing organization AGC Biologics said it will be manufacturing a SARS-CoV-2 vaccine for Swiss biotechnology firm Saiba.
Saiba is leveraging its Cucumber Mosaic Virus virus-like particle (VLP) platform technology to develop the vaccine, according to AGC. The company said that the recombinant VLP vaccine has the potential to quickly deliver a prophylaxis for COVID-19, and also has a scalable, high-yield, large-scale production capability, the firm said.
AGC also noted that the vaccine has been engineered to enhance immune responsiveness in elderly people.